WallStreetZenWallStreetZen

NASDAQ: FATE
Fate Therapeutics Inc Stock Ownership - Who owns Fate Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Fate Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jerome Charles BressiChief Regulatory and Quality Officer2025-01-105,980$1.55
$9.27kSell
Cindy TahlChief Legal Compliance Officer and Secretary2025-01-105,654$1.55
$8.76kSell
Bahram ValamehrPresident and CEO2025-01-108,705$1.54
$13.41kSell
Redmile Group LLCDirector2024-12-20341,633$1.68
$573.94kSell
Redmile Group LLCDirector2024-12-20397,964$1.68
$668.58kBuy
Redmile Group LLCDirector2024-12-201,084,936$1.68
$1.82MSell
Redmile Group LLCDirector2024-12-201,084,936$1.68
$1.82MBuy
Yuan XuDirector2024-08-06633$4.23
$2.68kSell

1 of 1

FATE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FATE insiders and whales buy or sell their stock.

FATE Shareholders

What type of owners hold Fate Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Redmile Group LLC22.43%25,712,223$29.57MInsider
Redmile Group LLC11.23%12,872,946$14.80MInstitution
Blackrock Inc9.32%10,681,779$12.28MInstitution
Vanguard Group Inc8.99%10,310,453$11.86MInstitution
Amir Nashat8.60%9,852,967$11.33MInsider
Polaris Venture Management Co V LLC8.59%9,841,933$11.32MInsider
Redco II Master Fund LP7.83%8,977,624$10.32MInsider
Schonfeld Strategic Advisors LLC6.80%7,794,513$8.96MInstitution
Citadel Advisors LLC3.74%4,289,159$4.93MInstitution
Jpmorgan Chase Co2.96%3,398,283$3.91MInstitution

1 of 3

FATE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FATE58.63%41.37%Net Buying
MOLN9.72%0.00%
NKTX63.53%36.47%Net SellingNet Selling
GNLX19.34%5.75%Net SellingNet Selling
ELTX9.95%70.40%Net Buying
View Top Biotech Stocks

Fate Therapeutics Stock Ownership FAQ

Who owns Fate Therapeutics?

Fate Therapeutics (NASDAQ: FATE) is owned by 84.14% institutional shareholders, 59.38% Fate Therapeutics insiders, and 0.00% retail investors. Redmile Group LLC is the largest individual Fate Therapeutics shareholder, owning 25.71M shares representing 22.43% of the company. Redmile Group LLC's Fate Therapeutics shares are currently valued at $29.57M.

If you're new to stock investing, here's how to buy Fate Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.